Group synergies coming through

Hardman & Co

Hardman & Co Report Report Downloads1pm Plc (LON:OPM) The FY’18 results delivered exactly what management promised. Loan origination was up 72%, revenue rose 78%, pre-tax profits increased 93%, while EPS grew 24%. The synergies from being a bigger group are emerging. Funding costs have fallen rapidly. Perhaps of greater importance, cross-group sales leads were £13m in 4Q FY’18. Not all will convert, but this represents nearly 10% of FY’18 origination. While we note a retiring director’s 6% stake may be viewed as a stock overhang, the implied May 2019 P/E of 6.7x and price to book of 0.9x, appears an anomaly given the downside risk highlighted in our sensitivity analyses.

FY’18 results: These results confirm all the company promises. Strong franchise growth has been delivered. Provisioning continues to be conservative (“general” provisions are over a third of the charge). Our updated credit sensitivity scenario (detailed below) indicates 2020E EPS above 2017, even in a hard landing.

Outlook: We have continued to accelerate investment into 2019 and this has led to a 2% trimming of EPS estimates for that year. We have introduced 2020 estimates showing further double-digit EPS growth. 1pm has previously announced an intent to increase dividend by 30% p.a. to FY’21.

Risks: Credit risk is a key factor and is managed by each business unit according to its own specific characteristics, with a group overview of controls. Funding is widely diversified and at least matches the duration of lending. Acquisitions would appear well priced and delivery of synergies provides earnings upside.

Valuation: We detailed the assumptions in our valuation approaches in our initiation note, “Financing powerhouse: A lunchtime treat”. The GGM indicates 116p and the DDM 70p (DDM normal payout 78p). The 2020E P/E (6.7x) and P/B (0.9x) appear an anomaly with 1pm’s profitability, growth and downside risk.

Investment summary: 1pm Plc offers strong earnings growth, in an attractive market, where management is tightly controlling risk. Targets to more than double the market capitalisation appear credible, with triggers to a re-rating being both fundamental (delivery of earnings growth, proof of cross-selling) and sentiment-driven (payback for management actively engaging the investor community). Profitable, growing companies generally trade well above NAV.

Share on:

Latest Company News

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers.

GSK gains priority FDA review for Jemperli in rectal cancer

GSK says the US FDA has accepted Jemperli for priority review in previously untreated stage II and III locally advanced rectal cancer.

Cora Gold secures interim renewal of Sanankoro II exploration permit

Cora Gold has secured the first interim renewal of the Sanankoro II exploration permit in south Mali as it progresses towards full permitting.

Likewise Group completes purchase of Corby distribution hub

Likewise Group plc has completed the freehold acquisition of a new Corby distribution hub for £9.57 million, with operations expected from January 2027.

Adaptix secures US Federal sales channel for Ortho350

Adaptix has secured a dedicated US federal sales channel for the Ortho350 through an exclusive reseller agreement with Spartan Medical.

MERLYN broadens ARYSTO range with new stone shower tray

MERLYN is expanding its premium ARYSTO range with ARYSTO Stone, a new shower tray launching in October 2026 with a focus on design, safety and practicality.

    Search